Composites with Ivacaftor and Colistin for Cystic Fibrosis and Bacterial Lung Infection Treatment

Back to all technologies
Download as PDF
Intravenous and oral antibiotics are not always effective for lung infections due to limited drug exposure at the infection site and bacterial resistance.

Researchers at Purdue University have developed a novel combination therapy of polymyxins for treating bacterial lung infections. Polymyxins have often been used as the last-line resort for infections caused by multi-drug resistant Gram-negative 'superbugs'; but Inhaled polymyxins can cause toxicity in the lungs. The novel formulation developed by Purdue researchers creates a powerful therapeutic option with better antibacterial killing and much-reduced toxicity than the polymyxins alone. The Purdue dry powder formulation shows promise as an inhaled therapy, with satisfactory stability and high aerosolization performance. This innovative inhalation formulation promises a life-saving option for patients suffering from bacterial lung infections, including people infected by multidrug-resistant Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacterales.

-Enhanced efficacy
-Decreased drug resistance
-Decreased toxicity

Potential Applications:

Related Publication:
Inhalable Nanocomposite Microparticles with Enhanced Dissolution and Superior Aerosol Performance
Mol. Pharmaceutics, Published online July 24, 2020
Mar 5, 2021

Mar 11, 2020
Provisional-Gov. Funding
United States
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486